Jan W Garber

US Patent:

43260250, Apr 20, 1982

Filed:

Dec 19, 1979

Appl. No.:

6/105468

Inventors:

Richard G. Buckles - Basel, CH
Jan W. Garber - McHenry IL

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

A01N 102
A61K 3514

US Classification:

435 2

Abstract:

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion includes a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, emulsified with sufficient hemo-compatible surfactant to stabilize the emulsion.

US Patent:

43755097, Mar 1, 1983

Filed:

Nov 6, 1981

Appl. No.:

6/318705

Inventors:

Richard G. Buckles - Basel, CH
Jan W. Garber - McHenry IL

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

A01N 102
A61K 3514

US Classification:

435 2

Abstract:

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion may include a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, with the emulsion containing sufficient hemo-compatible surfactant to stabilize the emulsion.

US Patent:

61143030, Sep 5, 2000

Filed:

May 3, 1999

Appl. No.:

9/304173

Inventors:

John Blue - Gurnee IL
Jan W. Garber - Barrington IL
Janet C. Gonder - Crystal Lake IL
Gary R. Marchand - Crystal Lake IL
Robert J. Przybelski - Fitchburg WI
Kathleen N. Stern - Lake Zurich IL

Assignee:

Baxter International, Inc. - Deerfield IL

International Classification:

A61K 3816

US Classification:

514 6

Abstract:

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.

US Patent:

40256189, May 24, 1977

Filed:

Mar 29, 1976

Appl. No.:

5/671515

Inventors:

Jan W. Garber - Palatine IL
De Wayne G. Davisson - Mount Prospect IL

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

A61K 3516
A61K 3700
C07G 700

US Classification:

424101

Abstract:

A blood collection system which comprises several blood compatible sealed bags connected together by blood compatible conduits. Means for separating cryoprecipitate from blood plasma are provided. This separation is made by a filtering means. The filtering means is positioned in the outlet of one of the bags of the system. After the blood cells have been removed by a prior step, the remaining blood plasma is collected in the bag which has the filtering means in the outlet. In this bag, the blood plasma is frozen and then slowly thawed. Factor VIII rich cryoprecipitate forms in this bag as part of the freezing and thawing process. As the plasma melts, it flows from the bag through the filtering means. The filtering means positioned in the outlet of the bag retains the cryoprecipitate. Thus, the separation of Factor VIII rich cryoprecipitate from the blood plasma is effected.

US Patent:

39865061, Oct 19, 1976

Filed:

Sep 3, 1974

Appl. No.:

5/503018

Inventors:

Jan W. Garber - Palatine IL
De Wayne G. Davisson - Mount Prospect IL

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

A61M 0514

US Classification:

128214D

Abstract:

A blood collection system which comprises several blood compatible sealed bags connected together by blood compatible conduits. Means for separating cryoprecipitate from blood plasma are provided. This separation is made by a filtering means. The filtering means is positioned in the outlet of one of the bags of the system. After the blood cells have been removed by a prior step, the remaining blood plasma is collected in the bag which has the filtering means in the outlet. In this bag, the blood plasma is frozen and then slowly thawed. Factor VIII rich cryoprecipitate forms in this bag as part of the freezing and thawing process. As the plasma melts, it flows from the bag through the filtering means. The filtering means positioned in the outlet of the bag retains the cryoprecipitate. Thus, the separation of Factor VIII rich cryoprecipitate from the blood plasma is effected.

US Patent:

59069740, May 25, 1999

Filed:

Aug 21, 1996

Appl. No.:

8/701812

Inventors:

John Blue - Gurnee IL
Jan W. Garber - Barrington IL
Janet C. Gonder - Crystal Lake IL
Gary R. Marchand - Crystal Lake IL
Robert J. Przybelski - Fitchburg WI
Kathleen N. Stern - Lake Zurich IL

Assignee:

Baxter International, Inc. - Deerfield IL

International Classification:

A61K 3816
A61K 39395
A61K 3514

US Classification:

514 6

Abstract:

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.